Preparation of solid lipid nanoparticles loaded with all-trans retinoic acid and their evaluation in vitro and in vivo

Yaoxue Xuebao

Volumn 40, Issue 1, 2005, Pages 71-75

  Hu, Lian Dong ^a   Tang, Xing ^a   Cui, Fu De ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

All trans retinoic acid; Compritol 888 ATO; Solid lipid nanoparticles; Ultrasonic technique

Indexed keywords

DRUG CARRIER; FATTY ACID; GLYCEROL BEHENATE; NANOMATERIAL; POLOXAMER; POLYSORBATE; RETINOIC ACID;

ANIMAL; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG STABILITY; MALE; PARTICLE SIZE; RAT; ULTRASOUND; WISTAR RAT;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FATTY ACIDS; MALE; NANOSTRUCTURES; PARTICLE SIZE; POLOXAMER; POLYSORBATES; RATS; RATS, WISTAR; TRETINOIN; ULTRASONICS;

EID: 33644699532     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Muller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state or the art [J]. Eur J Pharm Biopharm, 2000,50(1):161-77.
2. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization [J]. J Microencapsulation, 1999,16(2):205-213.
3. Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoarpticles and targeting effect on brain [J]. J Control Release, 1999,59(3):299-307.
4. Cavalli R, Fundaro A, Bargoni A, et al. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN) [J]. Pharmacol Res, 1999,44 (3):281-286.
5. Runge S, Mehnert W, Muller RH. SLN (solid lipid nanoparticles) a novel formulation for the oral administration of drugs [J]. Eur J Pharm Sci, 1996,4 (Suppl 1):S132.
6. Yang S, Zhu JB, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration [J]. Pharm Res, 1999,16(5):751-757.
7. Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications [J]. Adv Drug Deliv Rev, 2001,47(2-3):165-196.
8. Regazzi MB, Iacona I, Gervasutti C, et al. Clinical pharmacokinetics of tretinoin [J]. Clin Pharmacokinet, 1997,32(5):382-402.
9. Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy [J]. Chem Pharm Bull, 1995,43(8): 1412-1415.
10. Levy MY, Schutze W, Fuhrer C, et al. Characterization of diazepam submicron emulsion interface: role of oleic acid [J]. J Microencapsulation, 1994,11(1):79-92.
11. Takamura A, Ishii F, Noro S, et al. Study of intravenous hyperalimentation: effect of selected amino acids on the stability of intravenous fat emulsions [J]. J Pharm Sci, 1984,73(1):91-94.
12. Montassier P, Duchene D, Poelman MC. Inclusion complexes of tretinoin with cyclodextrins [J]. Int J Pharm, 1997,153(2):199-209.